DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for Myocardial Ischemia — screening already-approved drugs against its 38-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMyocardial Ischemia maps to a 38-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for myocardial ischemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipoprotein(a) (LPA) — LPA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TCE · 1.07 Å · ligand (2S)-3-phenyl-2-[(3R)-pyrrolidin-3-yl]propanoic acid (HWF). Experimental structure, not a prediction.
What the evidence adds up to
In 474 men with coronary artery disease or at high risk for it who underwent elective noncardiac surgery, 18 percent had a postoperative cardiac event. Postoperative myocardial ischemia occurred in 41 percent of monitored patients and was associated with a 2.8-fold increase in the odds of all adverse cardiac outcomes and a 9.2-fold increase in the odds of an ischemic event (cardiac death, myocardial infarction, or unstable angina). No other clinical, historical, or perioperative variable was independently associated with ischemic events in multivariate analysis.
In a mouse model, brief episodes of repetitive myocardial ischemia promoted growth of both large coronary arteries and the microvasculature. This growth improved myocardial perfusion after prolonged ischemia and protected against subsequent myocardial infarction. The study found that repetitive ischemia did not increase expression of classic proangiogenic factors but instead activated the innate immune system and recruited macrophages to growing blood vessels.
A 2013 review notes that current therapies for myocardial infarction cannot achieve satisfactory therapeutic effect and that gene therapy with angiogenesis factors offers new hopes. The review summarises research advance in the therapeutic effect of angiogenesis factors on ischemic heart disease but provides no patient data, no survival figures, and no controlled trial results.
What is still missing: large randomised controlled trials in humans testing whether promoting coronary growth via macrophage activation or angiogenesis factors reduces cardiac events or death. No such trial has been funded or completed. Patient stratification by baseline collateral status or immune profile has not been attempted. The mouse model has not been translated to a clinical protocol.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1990 · 1022 citations · open access
Association of Perioperative Myocardial Ischemia with Cardiac Morbidity and Mortality in Men Undergoing Noncardiac Surgery
AbstractBACKGROUND: Adverse cardiac events are a major cause of morbidity and mortality after noncardiac surgery. It is necessary to determine the predictors of these outcomes in order to focus efforts on prevention and treatment. Patients undergoing noncardiac surgery sometimes have postoperative cardiac events. It would be helpful to know which patients are at highest risk. METHODS: We prospectively studied 474 men with coronary artery disease (243) or at high risk for it (231) who were undergoing elective noncardiac surgery. We gathered historical, clinical, laboratory, and physiologic data during hospitalization and for 6 to 24 months after surgery. Myocardial ischemia was assessed by continuous electrocardiographic monitoring, beginning two days before surgery and continuing for two days after. RESULTS: Eighty-three patients (18 percent) had postoperative cardiac events in the hospital that were classified as ischemic events (cardiac death, myocardial infarction, or unstable angina) (15 patients), congestive heart failure (30), or ventricular tachycardia (38). Postoperative myocardial ischemia occurred in 41 percent of the monitored patients and was associated with a 2.8-fold increase in the odds of all adverse cardiac outcomes (95 percent confidence interval, 1.6 to 4.9; P less than 0.0002) and a 9.2-fold increase in the odds of an ischemic event (95 percent confidence interval, 2.0 to 42.0; P less than 0.004). Multivariate analysis showed no other clinical, historical, or perioperative variable to be independently associated with ischemic events, including cardiac-risk index, a history of previous myocardial infarction or congestive heart failure, or the occurrence of ischemia before or during surgery. CONCLUSIONS: In high-risk patients undergoing noncardiac surgery, early postoperative myocardial ischemia is an important correlate of adverse cardiac outcomes.
New England Journal of Medicine · 1976 · 668 citations
Medical Therapy of Acute Myocardial Infarction by Application of Hemodynamic Subsets
AbstractIn the broadest sense, current hospital therapy of acute myocardial infarction attempts to prevent, or promptly and effectively treat, the electrical and mechanical consequences of regional myocardial ischemia or infarction, while preserving jeopardized ischemic myocardium. Prevention and effective therapy of arrhythmias have largely been realized through the development of coronary-care units. The goals of prompt and effective therapy of disordered cardiac function and preservation of ischemic muscle, although far from achieved, have been greatly advanced in the past several years by the widespread use of hemodynamic monitoring. As a result, new concepts concerning the disease itself and new therapies have . . .
Journal of the American Heart Association · 2013 · 25 citations · open access
Repetitive Myocardial Ischemia Promotes Coronary Growth in the Adult Mammalian Heart
AbstractBACKGROUND: Coronary artery disease and ischemic cardiomyopathy represent the leading cause of heart failure and continue to grow at exponential rates. Despite widespread availability of coronary bypass surgery and percutaneous coronary intervention, subsequent ischemic events and progression to heart failure continue to be common occurrences. Previous studies have shown that a subgroup of patients develop collateral blood vessels that serve to connect patent and occluded arteries and restore perfusion to ischemic territories. The presence of coronary collaterals has been correlated with improved clinical outcomes; however, the molecular mechanisms governing this process remain largely unknown. METHODS AND RESULTS: To date, no mouse models of coronary arterial growth have been described. Using a closed-chest model of myocardial ischemia, we have demonstrated that brief episodes of repetitive ischemia are sufficient to promote the growth of both large coronary arteries and the microvasculature. Induction of large coronary artery and microvascular growth resulted in improvements in myocardial perfusion after prolonged ischemia and protected from subsequent myocardial infarction. We further show that repetitive ischemia did not lead to increased expression of classic proangiogenic factors but instead resulted in activation of the innate immune system and recruitment of macrophages to growing blood vessels. CONCLUSIONS: These studies describe a novel model of coronary angiogenesis and implicate the cardiac macrophage as a potential mediator of ischemia-driven coronary growth.
Utility of the angiogenesis factors in the management of ischemic heart disease
AbstractIschemic heart disease seriously damages people's health.Current therapies present a major challenge in the treatment of myocardium infarction,and can't achieve satisfactory therapeutic effect.Gene therapy especially the angiogenesis factors offered new hopes to treat the disease.In addition,this paper summarizes the research advance in the therapeutic effect of the angiogenesis factors on ischemic heart disease.
Key words:
Myocardial ischemia; Angiogenesis inducing agents; Gene therapy
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
